Mette Kalager ed drugs.

Mette Kalager, M.D ed drugs ., Marvin Zelen, Ph.D.D., and Hans-Olov Adami, M.D., Ph.D.: Effect of Screening Mammography on Breast-Cancer Mortality in Norway On the basis of several randomized medical trials,1-3 the World Health Organization concluded in 2002 that screening mammography for women between your ages of 50 and 69 years decreased the rate of death from breast cancer by 25 percent.4 Nevertheless, the use of screening mammography is debated, chiefly due to concern regarding methodologic limitations in a few of the randomized trials.5 Furthermore, the benefit of mammography when applied in a population-based service program remains poorly quantified.

In addition, patients needed to be 18 years or older; have adequate bone-marrow, liver, and renal function; and have an Eastern Cooperative Oncology Group performance status of 0 or 1 . The protocol is available with the full text of this content at NEJM.org. The initial author prepared the initial draft of the manuscript with input from the sponsor, and all of the coauthors subsequently provided insight and approved the manuscript. All of the decision was created by the authors to post the manuscript pertaining to publication. An unbiased data and protection monitoring plank evaluated the conduct frequently, evolving outcome, and protection of the study.